Earlybird Health Closes €173 Million New Fund to Focus on European Healthcare Innovations

Berlin-based Earlybird Health has closed its latest healthcare fund of €173 million to predominantly invest in European companies from the early development stage to advanced technologies nearing regulatory approval and commercialization, across healthcare sectors including digital health, diagnostics, medical devices, R&D tools, and biopharma.

With a team of more than 10 professionals, Earlybird Health brings a wealth of investment expertise to identify investment opportunities and provide financial and strategic support to its portfolio companies.

To augment investment team experience, Earlybird uses a proprietary in-house technology, Eagle Eye, for deal sourcing. Harnessing data aggregation and curation of multiple sources, this cutting-edge AI tool scouts new startups and gathers information for established entities. The versatile tool increases deal flow from stealth mode companies to crossover financing rounds, offering market intelligence through competitor analyses and trend reports.

Eagle Eye will soon be the driver of a more effective, efficient, and inclusive deal sourcing and due diligence process for our investment teams,” states Dr. Christoph Massner, Principal at Earlybird Health.

The new Earlybird Health Fund received support from major institutional investors across Europe, ranging from health insurers and strategic investors to public and private organisations across the entire region including British Patient Capital and German public health insurer BARMER.

To view the source version, please click HERE.

en_GBEnglish (UK)